<DOC>
	<DOCNO>NCT01897428</DOCNO>
	<brief_summary>To compare relative bioavailability pharmacokinetic characteristic newly develop bepotastine formulation , bepotastine salicylate , conventional formulation , bepotastine besilate , healthy subject single dose , randomize , open-label , 2-sequence -2period crossover study .</brief_summary>
	<brief_title>PK Comparisons Bepotastine Besilate 10 mg Bepotastine Salicylate 9.64 mg</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<mesh_term>Salicylic Acid</mesh_term>
	<criteria>subject age 20 45 year Body weight &gt; 50 kg ( case female &gt; 45 kg ) BMI 18 29 kg/m2 Signed date informed consent form meet criteria current FDA KFDA regulation subject acute condition . presence history affect ADME Clinically significant history current evidence hepatic , renal , gastrointestinal , hematologic abnormality Hepatitis B , hepatitis C , HIV infection reveal laboratory finding Any acute chronic disease A history hypersensitivity bepotastine A history alcohol drug abuse Participation another clinical trial within 2 month smoke &gt; 10 cigarette daily consumption 5 glass daily beverage contain xanthine derivative use medication potential affect study result within 10 day start study . medication inhibitor inducer DME include barbiturate within 1 month one abnormal lab finding like c. AST/ALT &gt; UNL ( upper normal limit ) x 1.5 Total bilirubin &gt; UNL x 1.5</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>